Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Search results

Found 9 matches for

First human trial of aerosol vaccine delivery launched

The Jenner Institute, in partnership with the Coler Lab at Seattle Children’s Research Institute (SCRI), is set to begin a new clinical trial to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-man aerosol mycobacterial challenge infection model with healthy adult volunteers.

Bangladesh malaria mass vaccine and drug administration trial begins

After more than a year of community engagement and preparation in 100 villages with 12,000 populations across the Chittagong Hill Tracts, the mass malaria vaccine (R21/Matrix M) and drug (DHA, piperaquine, and single low dose primaquine) administration study started on 15 Feb.

Trial results for first vaccine against blood-stage malaria show it is well-tolerated and offers effective protection

Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease – the first inoculation to do so.

Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus

Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.

First-in-human vaccine trial for deadly Nipah virus launched

First clinical trial participants received doses of the ChAdOx1 NipahB vaccine over the last week at University of Oxford. UK trial is first step to developing a vaccine against Nipah virus – a devastating disease mostly found in South-East Asia – that can be fatal in up to 75% of cases. The milestone clinical trial comes as the global health community marks the 25th anniversary of the first Nipah virus outbreaks. There are still no approved vaccines or treatments for the disease.

First volunteers receive vaccine for Crimean-Congo haemorrhagic fever in Oxford clinical trial

A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.

African Phase I HIV vaccine trial shows encouraging preliminary results

The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully.

MORU hepatitis work focusses on preventing mother-to-child transmission, high-at-risk populations, and remote communities

MORU Tropical Health Network researchers in Southeast Asia study various aspects of hepatitis B and C, infections that can lead to chronic liver diseases, and complications like liver cancer or cirrhosis. Researchers at MOCRU work on treatment for hepatitis C, a frequent opportunistic infection in HIV patients. MORU’s Clinical Pharmacology conducts two trials on possible treatments of hepatitis C. Hepatitis B is frequently transmitted from mother to child at birth, and SMRU researchers study mothers’ knowledge and behaviour, as well as prevention.

First-of-its-kind study found equine antitoxin is safe and effective for the treatment of tetanus in adults

A first-of-its kind randomised controlled trial compared two different antitoxin treatments for tetanus. A comparison of human and equine intramuscular antitoxin in adults found that intramuscular equine antitoxin is safe and effective for treating tetanus in adults. Addition of additional intrathecal (spinal) antitoxin does not add any benefit compared to treatment with intramuscular antitoxin alone.